Priceline continued a string of positive results from online travel companies with fourth-quarter earnings out late Thursday that crushed expectations, though its Q1 guidance fell short. Profit per share minus items rose 31% to $8.85, far above consensus estimates of $8.29. Revenue grew 29% vs. a year earlier to $1.54 billion, just beating forecasts for $1.52 billion. Both earnings and revenue have seen double-digit growth for at
Tesla Motors capped 2013 with Model S sales above expectations and an outlook for this year that sped by views, too. The company sees more than 35,000 deliveries in 2014, up at least 55% from the 22,477 cars sold last year. That amounted to nearly $2.5 billion in 2013 revenue for the luxury electric-car maker, ahead of the $2.4 billion analysts expected. Tesla (TSLA) stock zoomed 12% after hours Wednesday, after Q4 results beat
Generic drug giant Actavis agreed to buy Forest Laboratories for $25 billion in cash and stock Tuesday, making for the biggest deal yet in specialty pharma’s recent consolidation boom. Both stocks jumped on the news. Actavis (ACT) said the combined firm will have about $15 billion in annual sales, rivaling big pharma Bristol-Myers Squibb (BMY). Sales will be roughly split between branded and generic drugs. Actavis will pay $26.04